Scientists test new inhaled drug for scarred lungs
NCT ID NCT06992661
Summary
This is a first-in-human study to understand how a new inhaled drug, RJ026, moves through the body and how safe it is. It will enroll 84 people, including healthy volunteers and patients with interstitial lung disease (ILD), a condition that causes lung scarring. Researchers will give single doses of the drug, take many blood and lung fluid samples over 24 hours, and monitor participants for a week to gather initial safety and drug-level data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.